The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part I): muscle afferent block versus botulinum toxin-A in cervical and limb dystonias.
Botulinum toxin (BoNT) is an established mainstay treatment for dystonia. However, its use, especially in developing countries, is significantly limited by its cost. Chemodenervation with muscle afferent block (MAB) using lidocaine-ethanol may provide a more cost-effective alternative to traditional BoNT injections. A study comparing MAB with BoNT type-A in cases of X-linked dystonia-Parkinsonism (XDP) having cervical dystonia indicated a modest and short-lived efficacy with MAB, while a more robust efficacy in dystonia and pain parameters, lasting up to 11 weeks, was observed in the two BoNT type-A preparations (Dysport® and Botox®). In another study comparing BoNT type-A formulations for limb dystonia of XDP, a prior MAB was used to select target muscles for toxin injection. During toxin injections in the limb muscles, Dysport® and Botox® did not show significant differences with regard to global severity and disability scales, duration of effect, and adverse event (AE) profile. Dysphagia was the most common AE following BoNT type-A injections in cervical dystonia, while weakness was the most frequent AE noted with injections for limb dystonia. MAB injections carried a high incidence of dizziness and pain during injections. However, because MAB is a more cost-effective alternative that can be given repeatedly, it has been used in the XDP population while awaiting funds for BoNT type-A and/or for selecting muscles for injection as a test drug.
Department of Neurology and Psychiatry, University of Santo Tomas Hospital, Manila, Philippines. rrosales@info.com.ph
Raymond L
RL
Rosales
Mary Mildred Delgado-Delos
MM
Santos
Arlene R
AR
Ng
Rosalia
R
Teleg
Marita
M
Dantes
Lillian V
LV
Lee
Hubert H
HH
Fernandez
D000344:Afferent Pathways / Q000187:drug effects / Q000503:physiopathology; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D020821:Dystonic Disorders / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D005260:Female; D040181:Genetic Diseases, X-Linked / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D006801:Humans; D008297:Male; D009121:Muscle Denervation / Q000379:methods*; D009407:Nerve Block / Q000379:methods*; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology
D019274:Botulinum Toxins, Type A